Literature DB >> 33572109

Neuropsychiatric Consequences of Lipophilic Beta-Blockers.

Sabina Alexandra Cojocariu1, Alexandra Maștaleru1,2, Radu Andy Sascău1,3, Cristian Stătescu1,3, Florin Mitu1,2, Maria Magdalena Leon-Constantin1,2.   

Abstract

Beta-blockers are a class of drugs with important benefits in cardiovascular pathology. In this paper, we aim to highlight their adverse and therapeutic effects in the neuropsychiatric field. With respect to permeability, we would like to mention that most beta-blockers are lipophilic and can cross the blood-brain barrier. Observational studies show the presence of neuropsychiatric side effects when taking beta-blockers, and is the reason for which caution is recommended in their use in patients with depressive syndrome. From a therapeutic point of view, most current evidence is for the use of beta-blockers in migraine attacks, essential tremor, and akathisia. Beta-blockers appear to be effective in the treatment of aggressive behavior, beneficial in the prevention of posttraumatic stress syndrome and may play a role in the adjuvant treatment of obsessive-compulsive disorder, which is refractory to standard therapy. In conclusion, the relationship between beta-blockers and the central nervous system appears as a two-sided coin. Summarizing the neuropsychiatric side effects of beta-blockers, we suggest that clinicians pay special attention to the pharmacological properties of different beta-blockers.

Entities:  

Keywords:  beta-blockers; depression; fatigue; migraine; propranolol

Mesh:

Substances:

Year:  2021        PMID: 33572109      PMCID: PMC7914867          DOI: 10.3390/medicina57020155

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  100 in total

Review 1.  International classification of sleep disorders-third edition: highlights and modifications.

Authors:  Michael J Sateia
Journal:  Chest       Date:  2014-11       Impact factor: 9.410

2.  ADMET-score - a comprehensive scoring function for evaluation of chemical drug-likeness.

Authors:  Longfei Guan; Hongbin Yang; Yingchun Cai; Lixia Sun; Peiwen Di; Weihua Li; Guixia Liu; Yun Tang
Journal:  Medchemcomm       Date:  2018-11-30       Impact factor: 3.597

3.  Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.

Authors: 
Journal:  Cephalalgia       Date:  2018-01       Impact factor: 6.292

Review 4.  Pharmacological management for agitation and aggression in people with acquired brain injury.

Authors:  S Fleminger; R J Greenwood; D L Oliver
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 5.  β-blockers: Their new life from hypertension to cancer and migraine.

Authors:  Carlo Fumagalli; Niccolò Maurizi; Niccolò Marchionni; Diego Fornasari
Journal:  Pharmacol Res       Date:  2019-12-03       Impact factor: 7.658

6.  Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial.

Authors:  S Hirschmann; P N Dannon; I Iancu; O T Dolberg; J Zohar; L Grunhaus
Journal:  J Clin Psychopharmacol       Date:  2000-10       Impact factor: 3.153

7.  Delirium following vascular surgery: increased incidence with preoperative beta-blocker administration.

Authors:  Rita Katznelson; George Djaiani; Nicholas Mitsakakis; Thomas F Lindsay; Gordon Tait; Zeev Friedman; Marcin Wasowicz; W Scott Beattie
Journal:  Can J Anaesth       Date:  2009-08-27       Impact factor: 5.063

Review 8.  The hallucinating brain: a review of structural and functional neuroimaging studies of hallucinations.

Authors:  Paul Allen; Frank Larøi; Philip K McGuire; Andrè Aleman
Journal:  Neurosci Biobehav Rev       Date:  2007-08-15       Impact factor: 8.989

9.  Amyloid burden and neural function in people at risk for Alzheimer's Disease.

Authors:  Sterling C Johnson; Bradley T Christian; Ozioma C Okonkwo; Jennifer M Oh; Sandra Harding; Guofan Xu; Ansel T Hillmer; Dustin W Wooten; Dhanabalan Murali; Todd E Barnhart; Lance T Hall; Annie M Racine; William E Klunk; Chester A Mathis; Barbara B Bendlin; Catherine L Gallagher; Cynthia M Carlsson; Howard A Rowley; Bruce P Hermann; N Maritza Dowling; Sanjay Asthana; Mark A Sager
Journal:  Neurobiol Aging       Date:  2013-10-23       Impact factor: 4.673

Review 10.  Neuropsychiatric consequences of cardiovascular medications.

Authors:  Jeff C Huffman; Theodore A Stern
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

View more
  3 in total

1.  The association between cardiac drug therapy and anxiety among cardiac patients: results from the national DenHeart survey.

Authors:  Camilla Rotvig; Anne Vinggaard Christensen; Knud Juel; Jesper Hastrup Svendsen; Martin Balslev Jørgensen; Trine Bernholdt Rasmussen; Britt Borregaard; Lars Thrysoee; Charlotte Brun Thorup; Rikke Elmose Mols; Selina Kikkenborg Berg
Journal:  BMC Cardiovasc Disord       Date:  2022-06-20       Impact factor: 2.174

2.  Symptom Cluster Profiles Among Adults with Insomnia and Heart Failure.

Authors:  Samantha Conley; Sangchoon Jeon; Stephen Breazeale; Meghan O'Connell; Christopher S Hollenbeak; Daniel Jacoby; Sarah Linsky; Henry Klar Yaggi; Nancy S Redeker
Journal:  Behav Sleep Med       Date:  2022-04-07       Impact factor: 3.492

3.  Association between β-blocker dose and quality of life after myocardial infarction: a real-world Swedish register-linked study.

Authors:  Sophia Humphries; John Wallert; Katarina Mars; Claes Held; Robin Hofmann; Erik M G Olsson
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2022-06-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.